文献速递艾滋病与性传播感染

REPRIEVE试验:HIV感染者心血管疾病预防的重要研究平台

Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators.
PubMed 文献 · J Infect Dis · 2020-01-01

REPRIEVE是HIV领域规模最大的心血管疾病研究,2015至2019年纳入来自5大洲的7770名接受抗逆转录病毒治疗(ART)的HIV感染者,评估他汀类药物作为心血管疾病预防策略的效果。该试验及其子研究不仅评估心血管结局,还提供关于人群特征、合并症(肾功能不全、肌肉功能与衰弱、心肌脂肪变)以及不同全球疾病负担(GBD)区域ART模式、免疫功能和生殖衰老等丰富数据。

要点

  • REPRIEVE纳入7770名接受ART的HIV感染者,评估他汀用于心血管疾病预防。
  • 试验覆盖5大洲,数据反映不同GBD区域的 ethnic、种族和性别多样性。
  • 补充研究提供肾功能不全、衰弱、心肌脂肪变等合并症的详细表型数据。

核心结论

  • REPRIEVE是HIV领域规模最大的心血管疾病研究,将评估他汀作为心血管疾病预防策略的效果。
  • 该试验是获取HIV感染者人群特征和关键合并症数据的丰富来源,尤其跨GBD区域。

研究设计与样本

  • REPRIEVE为随机试验,2015至2019年纳入来自5大洲的7770名接受ART的HIV感染者。
  • 试验主要目的是评估他汀的心血管疾病预防效果,并设有评估冠状动脉斑块的子研究。

主要发现

  • 原文未报告具体结局数据。

关键数值与推荐

  • 原文未报告具体数值标准。

临床怎么用

  • REPRIEVE的数据可用于了解不同GBD区域HIV感染者的ART模式、免疫功能和合并症特征。
  • 该试验关注肾功能不全、肌肉功能与衰弱、心肌脂肪变等合并症,可供临床评估参考。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 to 2019 with sites across 5 continents, REPRIEVE will assess the effects of a statin as a cardiovascular disease prevention strategy in people with HIV (PWH) receiving antiretroviral therapy (ART). Although the primary purpose of REPRIEVE, and its substudy assessing coronary plaque, is to assess cardiovascular outcomes, the trial is a rich source of data on population characteristics and critical comorbidities in PWH, particularly across Global Burden of Disease (GBD) regions, reflective of the ethnic, racial, and gender diversity in this global epidemic. The purpose of this Supplement is to leverage the rich phenotyping in REPRIEVE, to provide data on detailed patterns of baseline ART and immune function by GBD region, reproductive aging among cisgender women, and data on the participation and clinical characteristics of transgender participants. We also leveraged REPRIEVE to assess critical comorbidities, including renal dysfunction, muscle function and frailty, and myocardial steatosis. REPRIEVE is a remarkable collaboration between funders, trial networks, clinical research sites, clinical and data coordinating centers, and willing participants who devoted their time to make the trial possible.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Grinspoon SK, Douglas PS, Hoffmann U, et al. Leveraging a Landmark Trial of Primary Cardiovascular Disease Prevention in Human Immunodeficiency Virus: Introduction From the REPRIEVE Coprincipal Investigators. J Infect Dis. 2020. PMID: 32645161. doi:10.1093/infdis/jiaa098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。